secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001193125-25-178022
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics expands ATM offering capacity by $360M to total $450M
-------------------------------------------------------------------------

- Increased ATM equity offering capacity by $360M; total authorized up to $450M under agreement with J.P. Morgan.
- As of Aug 11, 2025, approximately $45.8M remained available for sale under the prior $90M facility.
- New prospectus supplement filed Aug 11, 2025; terms unchanged (3% commission, at-the-market sales).
- Company retains discretion; no obligation to sell any shares under the agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000119312525178022/0001193125-25-178022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000119312525178022/d56029d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-178022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer